Boston Scientific Corporation
BSX-PA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$175.45B
Close$
Earnings Call Q3 2026
October 28, 2026 - AI Summary
Q3 2026 results missed on cyber impact; operational growth weak
- Organic revenue: +1.5% (below original guide +3% to +5%).
- Adjusted EPS: $0.73, down 3% YoY, below guidance range ($0.80–$0.82).
- Cybersecurity incident (previously reported): estimated ~300 bps drag on organic growth and ~$0.07 unfavorable EPS impact in Q3 (lost sales during an 8-business-day disruption + unfavorable manufacturing absorption and direct costs).
- Operations restored: all systems back up as of Sept 8.
Q4 2026 outlook: continued cyber-related pressure, but guidance still aims for stability
- Organic revenue: guided -1% to -3% (reflects cyber drag plus inventory replenishment effects).
- Adjusted EPS: $0.77–$0.79.
- Full-year 2026: +4% organic revenue growth and adjusted EPS $3.16–$3.18 (performance also impacted by margins and mix).
- Cyber expected to continue into Q4: ~200–300 bps impact; management expects it to burn off as customer inventory normalize (and EPS impact guided down to roughly $0.04–$0.05 in Q4).
Big-picture warning: 2027 expected to be the “trough,” mainly due to EP + Watchman cycle and pricing
- Management says 2027 will be challenging: expects difficulty growing sales and adjusted EPS in 2027 excluding Penumbra.
- 75% of business is still growing ~6–7%, but EP and Watchman are weighing on total company growth.
- Key reason given: market dynamics not improving in the near term + pricing headwinds in China; plus a new competitive launch impacting Watchman in 2027.
- Surprising/negative: They are explicitly guiding conservatively for 2027 even though they cite improving catalysts coming in later years.
Exclusive for Stockcircle Pro members
Sign up
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $175.45 Billion |
|---|---|
| Enterprise Value | $187.92 Billion |
| Earnings per Share | $1.96 |
| Beta | 0.8 |
| Outstanding Shares | 1,448,700,000 |
Return
| Return on Equity | 14.05% |
|---|---|
| Return on Assets | 7.75% |
| Return on Invested Capital | 10.79% |
Valuation & Multiples
| P/E Ratio | 17.71 |
|---|---|
| PEG | -81.46 |
| Price to Sales | 8.73 |
| Price to Book Ratio | 7.19 |
| Enterprise Value to Revenue | 8.87 |
| Enterprise Value to EBIT | 44.91 |
| Enterprise Value to Net Income | 53 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Boston Scientific Corporation
45,000 employees
CEO: Michael F. Mahoney
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The com...